FREE SHIPFree U.S. shipping on orders over $150Free U.S. shipping on orders over $150
Free U.S. shipping on orders over $150
Research-grade compound with certificate of analysis. Full analytical testing on every lot.
Survodutide is a dual GLP-1 and glucagon receptor agonist studied for its role in integrated metabolic regulation.
By combining appetite and satiety signaling with hepatic energy and lipid metabolism pathways, it has benefits on weight reduction, glycemic control, cardiometabolic risk, and fatty liver through coordinated endocrine signaling rather than single-pathway modulation.
Survodutide is a synthetic, long-acting dual-agonist peptide designed to activate both the glucagon receptor (GCGR) and the glucagon-like peptide-1 receptor (GLP-1R) [1].
This dual-receptor profile distinguishes survodutide from single-pathway incretin peptides and reflects an approach aimed at integrating energy expenditure and appetite regulation.
The side-effect profile observed with survodutide in clinical research appears consistent with other peptides that engage GLP-1–based pathways, with gastrointestinal effects such as nausea and discomfort reported as the most common events [2].
These effects are dose-dependent and prominent during rapid dose escalation.
Compared with GLP-1–only agonists, glucagon receptor activity introduces additional considerations related to hepatic glucose output and energy metabolism.
Survodutide enhances central satiety cues, slows gastric emptying, and reduces meal size, contributing to weight loss.
A Phase 2 RCT evaluated the safety, tolerability, and efficacy of survodutide in 387 adults overweight or obese without diabetes.
Participants were randomized to once-weekly subcutaneous survodutide (0.6 mg, 2.4 mg, 3.6 mg, or 4.8 mg) or placebo for 46 weeks (20 weeks dose escalation, 26 weeks maintenance) [3].
Survodutide administration resulted in:
Results can be visualized below:
|
Parameter |
Placebo |
Survodutide doses |
|||
|
0.6 mg |
2.4 mg |
3.6 mg |
4.8 mg |
||
|
Bodyweight (%) |
-2.8 |
-6.2 |
-12.5 |
-13.2 |
-14.9 |
|
Waist Circumference (cm) |
-4.0 |
-8.3 |
-15.0 |
-15.0 |
-16.0 |
|
Systolic Blood Pressure (mmHg) |
-2.5 |
-6.2 |
-8.1 |
-8.7 |
-8.6 |
|
Diastolic Blood Pressure (mmHg) |
-1.9 |
-3.3 |
-4.4 |
-4.3 |
-4.8 |
The trial demonstrates that dual GLP-1/glucagon receptor agonism produces clinically meaningful, dose-dependent weight loss with an acceptable tolerability profile.
Currently, clinical trials are underway to investigate survodutide’s effects on cardiovascular outcomes in patients with cardiovascular or kidney disease [4].
However, the peptide has been well studied in its potential for glycemic control.
A Phase 2 RCT evaluated the dose response effects of survodutide on glycemic control and body weight in 413 adults with type 2 diabetes receiving background metformin therapy [5].
Participants were randomized to once or twice-weekly survodutide at varying doses, placebo, or open-label semaglutide (1.0 mg once weekly) for 16 weeks.
Survodutide resulted in:
Results can be visualized below:
|
Parameter |
Placebo |
Survodutide weekly doses |
|||||
|
0.3 mg 1x |
0.9 mg 1x |
1.8 mg 1x |
2.7 mg 1x |
1.2 mg 2x |
1.8 mg 2x |
||
|
HbA1C (mmol) |
-1.62 |
-9.92 |
-15.95 |
-18.72 |
-17.01 |
-17.84 |
-18.38 |
|
Bodyweight Reduction > 5% |
- |
8% |
38% |
42.3% |
46% |
56.9% |
57.1% |
|
Bodyweight Reduction > 10% |
- |
2% |
6% |
13.5% |
16.0% |
25.5% |
34.7% |
The findings support further development of dual GLP-1/glucagon receptor agonism for metabolic disease management.
Fatty liver disease is closely linked to insulin resistance, excess caloric intake, and impaired lipid oxidation, pathways directly influenced by survodutide.
A Phase 2 RCT evaluated the safety and efficacy of survodutide in 293 adults with biopsy-confirmed MASH and liver fibrosis.
Participants were randomized to receive once-weekly subcutaneous survodutide (2.4 mg, 4.8 mg, or 6.0 mg) or placebo over 48 weeks, consisting of a 24-week dose-escalation phase followed by a 24-week maintenance phase [2].
Results showed that survodutide:
Results by dosage can be visualized below:
|
Parameter |
Placebo |
Survodutide doses (once weekly) |
||
|
2.4 mg |
4.8 mg |
6.0 mg |
||
|
Histological Improvement (%) |
14 |
47 |
62 |
43 |
|
Fibrosis Improvement by One Stage or more (%) |
22 |
34 |
36 |
34 |
GI adverse events were common:
Serious adverse events occurred at similar rates in the survodutide and placebo groups.
Dual GLP-1/glucagon receptor agonism with survodutide significantly improved features of MASH and reduced liver fat, prompting larger phase 3 trials for liver-related metabolic disease.
References
1 Wharton, S., le Roux, C. W., Kosiborod, M. N., Platz, E., Brueckmann, M., Jastreboff, A. M., et al. (2025) Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZETM-1 and -2). Obesity (Silver Spring), Wiley 33, 67–77
2 Sanyal, A. J., Bedossa, P., Fraessdorf, M., Neff, G. W., Lawitz, E., Bugianesi, E., et al. (2024) A phase 2 randomized trial of survodutide in MASH and fibrosis. N. Engl. J. Med., Massachusetts Medical Society 391, 311–319
3 le Roux, C. W., Steen, O., Lucas, K. J., Startseva, E., Unseld, A. and Hennige, A. M. (2024) Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol., Elsevier BV 12, 162–173
4 Kosiborod, M. N., Platz, E., Wharton, S., le Roux, C. W., Brueckmann, M., Ajaz Hussain, S., et al. (2024) Survodutide for the treatment of obesity: Rationale and design of the SYNCHRONIZE cardiovascular outcomes trial. JACC Heart Fail., Elsevier BV 12, 2101–2109
5 Blüher, M., Rosenstock, J., Hoefler, J., Manuel, R. and Hennige, A. M. (2024) Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial. Diabetologia, Springer Science and Business Media LLC 67, 470–482
Every lot undergoes five independent assays before release. Results are published in the lot-specific Certificate of Analysis.
Every lot undergoes our 4-panel testing protocol: HPLC purity analysis, ESI-MS identity confirmation, LAL endotoxin screening, and amino acid analysis (for peptides >15 residues). Full analytical data is published in the Certificate of Analysis for each lot.
Lyophilized peptides should be stored at -20°C or below for long-term stability. Once reconstituted, peptides should be stored at 2–8°C and used within a reasonable timeframe depending on the specific compound. Avoid repeated freeze-thaw cycles. Always store in a dry environment away from direct light.
Orders placed before noon PST, Monday–Saturday, ship the same day. We offer free standard shipping on orders over $150. All orders are shipped in insulated packaging with ice packs when necessary. Standard delivery typically takes 2–4 business days within the continental US.
No. All compounds sold by Genesis Peptides are strictly for in vitro and preclinical laboratory research purposes only. They are not approved for human consumption, therapeutic use, or diagnostic purposes. By purchasing, you confirm the products will be used solely for legitimate research applications.
A Certificate of Analysis (COA) is a document issued by our analytical laboratory that reports the results of all quality control tests performed on a specific lot of product. Each COA includes HPLC chromatograms, mass spectra, endotoxin results, and amino acid analysis where applicable. COAs are available in our COA Library for every lot we have shipped.
Yes. We offer volume pricing for universities, research institutions, and laboratories with recurring needs. Discounts begin at 10+ units and scale with volume. Contact our team for a custom quote tailored to your research requirements.
Research Use Only. All findings described above are derived from preclinical studies (animal models and in vitro experiments). Survodutide is not approved by the FDA for any diagnostic or therapeutic use in humans. Genesis Peptides makes no claims regarding human clinical efficacy. This product is sold exclusively for laboratory research.
FOR RESEARCH USE ONLY — Products are sold exclusively for in vitro and preclinical laboratory research. Not for human consumption or administration. Not intended for diagnostic or therapeutic use. These statements have not been evaluated by the FDA.
